Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
2,127 stopped studies mapped to Secondary Malignant Neoplasm and descendants · 91% state a reason
Over the 2,127 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT04801472 | Optimisation of Potential Dental Implant Sites Protection for Rehabilitation in Patients…(OPPIDOM) | N/A | terminated | Mar 17, 2021 | Institut de cancérologie Strasbourg Europe | organisationnal reason | Other (stated, no rule matched) |
| NCT06408168 | Phase II Study of REPotrectinib With or Without Fulvestrant in Patients With Hormone… | Phase 2 | terminated | May 10, 2024 | M.D. Anderson Cancer Center | \<75% Participation | Other (stated, no rule matched) |
| NCT04805788 | Stereotactic Body Proton Radiotherapy for the Treatment of Liver Cancer | Phase 2 | terminated | Mar 18, 2021 | Mayo Clinic | slow accrual | Enrollment / accrual |
| NCT05553522 | Tucatinib, Trastuzumab, and Capecitabine With SRS for Brain Metastases From HER-2… | Phase 1 | terminated | Sep 23, 2022 | Baptist Health South Florida | Slow enrollment | Enrollment / accrual |
| NCT06649682 | 68Ga-NYM096/177Lu-NYM096 in Metastatic ccRCC(NYCRRLT) | Phase 1 | suspended | Oct 21, 2024 | Peking Union Medical College Hospital | This trial has been suspended given the concerns of stomach adverse effect in the first dose of… | Safety / toxicity |
| NCT04986852 | Olinvacimab With Pembrolizumab in Patients With mTNBC | Phase 2 | terminated | Aug 3, 2021 | PharmAbcine | Subject recruitment issues and follow-up study plans | Enrollment / accrual |
| NCT07283848 | Zimberelimab + Domvanalimab in Gastroesophageal Adenocarcinoma | Phase 2 | withdrawn | Dec 16, 2025 | Massachusetts General Hospital | The pharmaceutical company is not moving forward with this intervention due to lack of efficacy. | Efficacy / futility |
| NCT05977322 | A Phase I Study of [177Lu]Lu-FF58 in Patients With Advanced Solid Tumors. | Phase 1 | terminated | Aug 4, 2023 | Novartis Pharmaceuticals | The decision was not based on any safety concerns | Safety / toxicity |
| NCT06626256 | STIL101 for Injection for the Treatment of Locally Advanced, Metastatic or Unresectable… | Phase 1 | withdrawn | Oct 3, 2024 | City of Hope Medical Center | no resource | Other (stated, no rule matched) |
| NCT03042169 | Surgical Resection Plus Chemotherapy Versus Chemotherapy Alone in Oligometastatic Stage…(SURGIGAST) | Phase 3 | terminated | Feb 3, 2017 | University Hospital, Lille | default inclusion | Other (stated, no rule matched) |
| NCT03225547 | Study of Pembrolizumab and Mifepristone in Patients With Advanced HER2-negative Breast… | Phase 2 | terminated | Jul 21, 2017 | University of Chicago | side effects (rash) | Other (stated, no rule matched) |
| NCT04831138 | Non-Contrast Perfusion Using Arterial Spin Labeled MR Imaging for Assessment of Therapy… | N/A | terminated | Apr 5, 2021 | University of Texas Southwestern Medical Center | The treatment landscape changed and hence unable to recruit patients undergoing only… | Enrollment / accrual |
| NCT06603155 | Time Restricted Eating (TRE) in Metastatic Head and Neck Squamous Cell Cancer (mHNSCC) or… | N/A | withdrawn | Sep 19, 2024 | Duke University | Changing priorities of portfolio | Sponsor / business decision |
| NCT05044676 | Immune Cells as a New Biomarker of Response in Patients Treated by Immunotherapy for…(IMMUNOCELL) | — | terminated | Sep 16, 2021 | Assistance Publique - Hôpitaux de Paris | Abandon of study | Other (stated, no rule matched) |
| NCT05171166 | Neoadjuvant HAIC of TACE Plus Donafenib in BCLC B Stage HCC: a Multi-center Randomized… | Phase 2 / Phase 3 | terminated | Dec 28, 2021 | Peking University | Difficult to enroll participants | Enrollment / accrual |
| NCT05668949 | Phase I/II Open Label Study Evaluating the Safety and Efficacy of Combining STAT3… | Phase 1 / Phase 2 | withdrawn | Dec 30, 2022 | M.D. Anderson Cancer Center | PI requested | Other (stated, no rule matched) |
| NCT04445064 | Activity and Safety of Peptide-based Immunotherapy in Patients With Squamous Cell…(HN1901) | Phase 2 | terminated | Jun 24, 2020 | Cliniques universitaires Saint-Luc- Université Catholique de Louvain | unmet primary endpoint | Other (stated, no rule matched) |
| NCT05652868 | Clinical Study of Antibody-Drug Conjugate MYTX-011 in Subjects With Non-Small Cell Lung… | Phase 1 | terminated | Dec 15, 2022 | Mythic Therapeutics | Business decision | Sponsor / business decision |
| NCT06347809 | DNA Methylation in Adenocarcinoma of the Prostate: Analysis of Validated Biomarkers in… | — | terminated | Apr 4, 2024 | Mayo Clinic | Closed to consolidate enrollment under another related study | Enrollment / accrual |
| NCT02364713 | MV-NIS or Investigator's Choice Chemotherapy in Treating Patients With Ovarian,… | Phase 2 | terminated | Feb 18, 2015 | Mayo Clinic | poor accrual | Enrollment / accrual |
| NCT06818305 | Efficacy and Safety of Finerenone and Empagliflozin in Delaying Renal Function…(EmFin-Nx) | Phase 2 | terminated | Feb 10, 2025 | Jinling Hospital, China | The patient enrollment rate is proceeding too slowly | Enrollment / accrual |
| NCT05289830 | Escitalopram to Placebo in Patients With Localized Pancreatic Cancer | Phase 2 | terminated | Mar 21, 2022 | Case Comprehensive Cancer Center | Slow accrual | Enrollment / accrual |
| NCT05583110 | Efficacy and Safety of the Combination of Trastuzumab Plus TUCAtinib Plus viNorelbine in…(TrasTUCAN) | Phase 2 | terminated | Oct 17, 2022 | Spanish Breast Cancer Research Group | The study was closed early due to safety concerns and an unfavorable benefit-risk balance.… | Safety / toxicity |
| NCT07084909 | Piflufolastat F 18 PET/CT in Patients With Suspected, or at High Risk for Metastatic ccRCC(HARRIER) | Phase 2 / Phase 3 | withdrawn | Jul 25, 2025 | Lantheus Medical Imaging | Operational challenges in patient enrollment | Enrollment / accrual |
| NCT03260504 | Aldesleukin and Pembrolizumab in Treating Patients With Advanced or Metastatic Kidney… | Phase 1 | terminated | Aug 24, 2017 | University of Washington | Insufficient funding | Funding |
| NCT05845307 | Randomized Pre-surgical Window-of-Opportunity Trial of TTI-101 in Patients With Stage… | Early Phase 1 | withdrawn | May 6, 2023 | M.D. Anderson Cancer Center | 0 participants | Other (stated, no rule matched) |
| NCT04106531 | Validation of a Quality of Life Metric "Prolac-10"(Prolac-10) | — | terminated | Sep 27, 2019 | Ohio State University | Investigator leaving institution | Investigator |
| NCT05064111 | Utility of Adding MR Fusion to Standard US Guided Prostate Biopsy | — | suspended | Oct 1, 2021 | University of Arizona | Per PI, the project start is on suspension. | Other (stated, no rule matched) |
| NCT04779151 | Basket Trial Exploring the Efficacy and Safety of the Combination of Niraparib and…(NIRADO) | Phase 2 | terminated | Mar 3, 2021 | Gustave Roussy, Cancer Campus, Grand Paris | Abandon of the partner, GSK | Other (stated, no rule matched) |
| NCT05252416 | (VELA) Study of BLU-222 in Advanced Solid Tumors | Phase 1 | terminated | Feb 23, 2022 | Blueprint Medicines Corporation | This trial was terminated prior to the initiation of Phase 2 for reasons not due to safety concerns. | Safety / toxicity |
| NCT04725331 | A Clinical Trial Assessing BT-001 Alone and in Combination With Pembrolizumab in… | Phase 1 / Phase 2 | terminated | Jan 26, 2021 | Transgene | Sponsor decision following completion of Phase I part not driven by safety reason | Safety / toxicity |
| NCT06320080 | Clinical Study of TQB2223 Injection Combined With AK105 Injection in the Treatment of… | Phase 1 | terminated | Mar 20, 2024 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | This study was closed due to business reasons. Closure was not prompted by any safety or efficacy… | Safety / toxicity |
| NCT01946100 | Treatment of Multifocal Lung Adenocarcinoma | N/A | terminated | Sep 19, 2013 | Mayo Clinic | Funding ended prior to completion of enrollment. | Enrollment / accrual |
| NCT05954143 | Trial of BDC-1001 +/- Pertuzumab in Subjects With HER2-Positive Metastatic Breast Cancer | Phase 2 | terminated | Jul 20, 2023 | Bolt Biotherapeutics, Inc. | Sponsor Decision | Sponsor / business decision |
| NCT04370509 | Pembrolizumab With or Without Axitinib for Clear Cell Kidney Cancer in Patients… | Phase 2 | terminated | May 1, 2020 | University of California, San Francisco | Collaborating sponsor decision | Sponsor / business decision |
| NCT04854499 | Study of Magrolimab Combination Therapy in Patients With Head and Neck Squamous Cell…(ELEVATE HNSCC) | Phase 2 | terminated | Apr 22, 2021 | Gilead Sciences | Sponsor decision to terminate study | Sponsor / business decision |
| NCT05417386 | FOLFIRINOX + NIS793 in Pancreatic Cancer | Phase 1 | terminated | Jun 14, 2022 | Colin D. Weekes, M.D., PhD | NIS793 is no longer being developed | Other (stated, no rule matched) |
| NCT06994299 | A Pilot Trial of Preoperative Irradiation With the STRIDE (Single Dose of Tremelimumab…(PRISM) | Phase 2 | withdrawn | May 29, 2025 | Weill Medical College of Cornell University | Drug and financial support not available for the study. | Funding |
| NCT05256381 | A Study of SOT101 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety… | Phase 2 | terminated | Feb 25, 2022 | SOTIO Biotech AG | Due to lack of expected efficacy shown at the time of the interim analysis | Efficacy / futility |
| NCT05364944 | A Study to Assess the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of…(OXTEND-01) | Phase 1 | terminated | May 6, 2022 | Debiopharm International SA | The recruitment was halted for strategic reasons | Enrollment / accrual |
| NCT06052852 | Study of BDC-3042 as Single Agent and in Combination With Cemiplimab in Patients With… | Phase 1 | terminated | Sep 25, 2023 | Bolt Biotherapeutics, Inc. | Sponsor decision | Sponsor / business decision |
| NCT02936102 | A Study of FAZ053 Single Agent and in Combination With PDR001 in Patients With Advanced… | Phase 1 | terminated | Oct 18, 2016 | Novartis Pharmaceuticals | The early termination was based on a business decision that FAZ053 would no longer be formulated… | Safety / toxicity |
| NCT07178665 | Pilot Trial of Preop Partial Radiation in Breast Cancer Patients | Phase 1 | suspended | Sep 17, 2025 | Rutgers, The State University of New Jersey | 10th patient enrolled; interim analysis to be completed by HROC after 3-month follow-up completed… | Efficacy / futility |
| NCT03979508 | Abemaciclib in Treating Patients With Surgically Resectable, Chemotherapy Resistant,… | Phase 2 | terminated | Jun 7, 2019 | Mayo Clinic | The primary biomarker (CD8/FOXP3) was rarely observed to be \< 1.6 in residual tumors examined in… | Other (stated, no rule matched) |
| NCT05119335 | A Study of NKT2152, a HIF2α Inhibitor, in Patients With Advanced Clear Cell Renal Cell… | Phase 1 / Phase 2 | terminated | Nov 15, 2021 | NiKang Therapeutics, Inc. | This study was terminated as a result of Sponsor portfolio reprioritization. | Sponsor / business decision |
| NCT05935748 | Ph2 Study NKT2152 With Palbociclib & Sasanlimab in Subjects With Advanced Clear Cell… | Phase 2 | terminated | Jul 7, 2023 | NiKang Therapeutics, Inc. | This study was terminated as a result of Sponsor portfolio reprioritization. | Sponsor / business decision |
| NCT04504916 | A Study of Zilovertamab Vedotin (MK-2140/VLS-101) in Participants With Solid Tumors… | Phase 2 | terminated | Aug 7, 2020 | VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Business reasons | Sponsor / business decision |
| NCT05194735 | Phase I/II Study of Autologous T Cells to Express T-Cell Receptors (TCRs) in Subjects… | Phase 1 / Phase 2 | terminated | Jan 18, 2022 | Alaunos Therapeutics | Funding | Funding |
| NCT05252390 | NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients… | Phase 1 | terminated | Feb 23, 2022 | Nuvation Bio Inc. | The Sponsor has achieved its objectives. | Other (stated, no rule matched) |
| NCT04958785 | Study of Magrolimab Combination Therapy in Patients With Non-Surgically Removable Locally…(ELEVATE TNBC) | Phase 2 | terminated | Jul 12, 2021 | Gilead Sciences | Sponsor decision to terminate study. | Sponsor / business decision |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Jan 5, 2026source: clinicaltrials